✦ LIBER ✦

Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double-blind, placebo-controlled trial

✍ Scribed by J. M. Meijer; P. M. Meiners; A. Vissink; F. K. L. Spijkervet; W. Abdulahad; N. Kamminga; E. Brouwer; C. G. M. Kallenberg; H. Bootsma

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 175 KB
Volume: 62
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.27314

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Etanercept in Sjögren's syndrome: A twel

Etanercept in Sjögren's syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial

✍ Vidya Sankar; Michael T. Brennan; Marc R. Kok; Rose Anne Leakan; Janine A. Smith 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

## Abstract ## Objective To assess the safety and potential efficacy of etanercept in the treatment of Sjögren's syndrome (SS). ## Methods This pilot study was a 12‐week randomized, double‐blind, placebo‐controlled trial of etanercept, with 14 subjects in each group. Patients received 25 mg of e

Inefficacy of infliximab in primary Sjög

Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS)

✍ Xavier Mariette; Philippe Ravaud; Serge Steinfeld; Gabriel Baron; Joelle Goetz; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

## Objective: There is no effective treatment for patients with primary sjögren's syndrome (ss). since tumor necrosis factor alpha (tnf alpha) could be a key element in the pathogenesis of primary ss, we conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the eff

B cell reconstitution and T helper cell

B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: A double-blind, placebo-controlled study

✍ W. H. Abdulahad; J. M. Meijer; F. G. M. Kroese; P. M. Meiners; A. Vissink; F. K. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 365 KB 👁 1 views

A double-blind, randomized, placebo-cont

A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca

✍ Dianne Petrone; John J. Condemi; Rose Fife; Oscar Gluck; Stanley Cohen; Paul Dal 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB

Rituximab in patients with primary progr

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro

Methotrexate treatment in juvenile local

Methotrexate treatment in juvenile localized scleroderma: A randomized, double-blind, placebo-controlled trial

✍ Francesco Zulian; Giorgia Martini; Cristina Vallongo; Fabio Vittadello; Fernanda 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 2 views